Navigation Links
AbbVie Reports Third-Quarter 2013 Financial Results
Date:10/25/2013

ns.  Sales increased in the quarter despite the decline in TriCor/Trilipix sales due to the loss of exclusivity.  Excluding TriCor/Trilipix sales and foreign exchange, sales increased 10.9 percent in the quarter.  
  • Sales growth was driven by the continued strength of HUMIRA.  Global HUMIRA sales increased 19.1 percent on both a reported and operational basis.  U.S. HUMIRA sales grew 22.3 percent.  Total company sales growth was also driven by strong growth from other products including Synthroid, Creon, Zemplar and Duodopa.
  • Third-quarter adjusted gross margin ratio was 79.7 percent, excluding intangible asset amortization and other specified items.  Gross margin strength in the quarter was driven by operational efficiencies and product mix, including strong HUMIRA sales and better-than-expected lipid performance despite loss of exclusivity.  The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 76.6 percent.  
  • Adjusted selling, general and administrative (SG&A) expense was 26.1 percent of sales in the third quarter, reflecting continued investment in our growth brands.  On a GAAP basis, SG&A was 27.1 percent of sales.
  • Adjusted research and development (R&D) was 15.2 percent of sales in the quarter, reflecting funding actions in support of our emerging mid- and late-stage pipeline assets and the continued pursuit of additional HUMIRA indications.  On a GAAP basis, R&D was 15.3 percent of sales.
  • Net interest expense was $69 million, and the adjusted tax rate was 22.3 percent in the quarter.  On a GAAP basis, the third-quarter tax rate was 25.0 percent.
  • Third-quarter diluted earnings per share were $0.60 on a GAAP basis.  Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $0.82, above the company's previous guidance range.  

  • '/>"/>
    SOURCE AbbVie
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. AbbVie Named a Science Top Employer
    2. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    3. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    4. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
    6. AbbVie Declares Quarterly Dividend
    7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
    8. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
    9. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
    10. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
    11. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
    (Date:8/28/2015)... 28, 2015 The report "Eubiotics Market by Type ... Ruminant, and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends ... for Eubiotics was valued at USD 4.62 Billion in 2014 ... at a CAGR of 7.4% from 2015 to 2020. ...
    (Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
    Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
    ... Calif., March 15, 2011 XTIO2 INC ... -nominees with the XTI ANTI-GERM / ANTI-VOC / ... and XTI™  Nano-Facemask . It is the ... against germs transmitted via air and contact surfaces. The ...
    ... FRANCISCO, March 15, 2011 Motion Therapeutics, Inc. ... for balance and mobility disorders, today announced that researchers ... a NIH Recovery Act Grant to study the effects ... and mobility in people with MS. ...
    Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
    (Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
    (Date:8/29/2015)... ... 2015 , ... Dr. Tim Novelli, DC., Founder and President of the Patriot ... of the chiropractic field in the military. All too often VA hospitals treat patients ... made available to the VA program over a decade ago, the reality is that ...
    (Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
    (Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
    (Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
    Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
    ... Should physicians be banned from assisting in a lethal ... A recent ruling by the American Board of Anesthesiology ... punishment, and other medical boards may act similarly. An ... concludes that decertification of physicians participating in lethal ...
    ... HealthDay Reporter , THURSDAY, June 9 (HealthDay News) ... disease among kidney patients by as much as 25 percent, ... ever conducted. "People with kidney disease are at a ... Dr. Colin Baigent, a professor of epidemiology at the University ...
    ... in the Clinical Neuropsychologist (e-publication ahead of ... in the brain development of preschool children with symptoms ... the brain important for cognitive and motor control was ... Novel for its use of neuroimaging in very young, ...
    ... Sheffield,s School of Health and Related Research (ScHARR) has developed ... been accepted for use by the Department of Health. ... Jacques and James Fotheringham, were commissioned in January 2011 by ... index to look at deaths following a hospital admission. In ...
    ... , Bethesda, MD Vaccinating children around the world against ... past several decades. Now new opportunities exist to overcome remaining ... according articles in the June 2011 edition of Health ... from the Bill & Melinda Gates Foundation. Last ...
    ... into a wallet or pursebut it could mean the difference between ... stores personal medical data (e.g. information on existing medical conditions, allergies ... enabling the data to be accessed in just a few moments. ... have been trialled in the UK. This working prototype has ...
    Cached Medicine News:Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 3Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 2Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 3Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:New hospital mortality rate index to be used across UK 2Health News:New hospital mortality rate index to be used across UK 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 2Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 4Health News:MyCare -- the 'card' that could save your life 2
    ... knee system was designed to ... between all articulating surfaces and ... with wear in order to ... with normalized quadriceps and patellar ...
    ...
    ...
    ...
    Medicine Products: